Biblio

33557 resultats trouvés
P
Abis L, Loubet B, Ciuraru R, Lafouge F, Dequiedt S, Houot S, Maron PAlain, Bourgeteau-Sadet S.  2018.  Profiles of volatile organic compound emissions from soils amended with organic waste products. SCIENCE OF THE TOTAL ENVIRONMENT. 636:1333-1343.
Lechenet M, Makowski D, Py G, Munier-Jolain N.  2016.  Profiling farming management strategies with contrasting pesticide use in France. AGRICULTURAL SYSTEMS. 149:40-53.
Pericart S, Tosolini M, Gravelle P, Rossi C, Traverse-Glehen A, Amara N, Franchet C, Martin E, Bezombes C, Laurent G et al..  2018.  Profiling Immune Escape in Hodgkin's and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining. CANCERS. 10:415.
Bunel M, Tovar E.  2021.  Profit, morality and discrimination. APPLIED ECONOMICS. 53:4692-4712.
De Bono JS, Hussain M, Thiery-Vuillemin A, Mateo J, A. Sartor O, Chi KN, Fizazi K, Twardowski P, Agarwal N, Sandhu SKaur et al..  2017.  PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration.. JOURNAL OF CLINICAL ONCOLOGY. 35
Rigaud C., Abbas R., Simonin M., Le Mouel L., Peraira V., Minard-Colin V., Geoerger B., Brugieres L..  2019.  Profound and Sustained Response with ALK Inhibitors in Patients with CNS Relapse or Progressive ALK- Positive Anaplastic Lymphoma. PEDIATRIC BLOOD & CANCER. 66:S267-S268.
Hussain M., Mateo J., Fizazi K., Saad F., Shore N.D, Sandhu S., Chi K.N, Sartor O., Agarwal N., Olmos D. et al..  2019.  PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. ANNALS OF ONCOLOGY. 30:881+.
Sandhu S.K, Hussain M., Mateo J., Fizazi K., Saad F., Shore N., Chi K., Sartor O., Agarwal N., Olmos D. et al..  2019.  PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. ANNALS OF ONCOLOGY. 30
Feyerabend S., Hussain M., Mateo J., Fizazi K., Saad F., Shore N., Sandhu S., Chi K., Sartor O., Agarwal N. et al..  2020.  Profound: Phase III Study of the Efficacy and Safety of Olaparib versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Homologous Recombination Repair Gene (HRR) Alterations. ONCOLOGY RESEARCH AND TREATMENT. 43:71-72.
Sandhu S, Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Chi K, Sartor O, Agarwal N, Olmos D et al..  2019.  PROfound: Phase III study of the efficacy and safety of olaparib versus enzalutamide or abiraterone acetate in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair gene mutations (HRRm). ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. 15:122.
Guillon H, Mugnier J-L, Buoncristiani J-F.  2018.  Proglacial sediment dynamics from daily to seasonal scales in a glaciated Alpine catchment (Bossons glacier, Mont Blanc massif, France). EARTH SURFACE PROCESSES AND LANDFORMS. 43:1478-1495.
Tougeron D, Sueur B, Zaanan A, de la Fouchardiere C, Sefrioui D, Lecomte T, Aparicio T, Guetz GDes, Artru P, Hautefeuille V et al..  2020.  Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study. INTERNATIONAL JOURNAL OF CANCER. 147:285-296.
Derosiere A, Nicolai V, Malka D, Pozet A, Lazartigues J, Turpin A, Tougeron D, Walter T, Artru P, Bachet J-B et al..  2019.  Prognosis and chemosensitivity of non-V600E BRAF mutations in metastatic colorectal carcinoma (mCRC): An AGEO French multicenter retrospective cohort.. JOURNAL OF CLINICAL ONCOLOGY. 37
Derquin F, Floquet A, Lotz JPierre, Edeline J, Alexandre J, Pautier P, Ferron G, Oudard S, Plesse CLefeuvre, Vegas H et al..  2018.  Prognosis factors in malignant ovarian germ cell tumors (MOGCT): retrospective analysis of 147 cases prospectively included in the French network for Rare Malignant Ovarian Tumors (TMRO) & GINECO group. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 28:69-70.
Derquin F, Floquet A, Lotz JPierre, Edeline J, Alexandre J, Pautier P, Ferron G, Oudard S, Plesse CLefeuvre, Vegas H et al..  2018.  Prognosis factors in malignant ovarian germ cell tumors (MOGCT): retrospective analysis of 147 cases prospectively included in the French network for Rare Malignant Ovarian Tumors (TMRO) & GINECO group. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 28:69-70.
Karaer S, Eberst G, Claude F, Laurent L, Meurisse A, Roux-Claude P, Barnig C, Bouiller K, Chirouze C, Behr J et al..  2021.  Prognosis factors influencing three-month respiratory outcomes in intensive care unit survivors after COVID-19 pneumonia. EUROPEAN RESPIRATORY JOURNAL. 58
Fauchier L, Clementy N, Bisson A, Stamboul K, Ivanes F, Angoulvant D, Babuty D, Lip GYH.  2017.  Prognosis in patients with atrial fibrillation and a presumed ``temporary cause'' in a community-based cohort study. CLINICAL RESEARCH IN CARDIOLOGY. 106:202-210.
Vernerey D, Hammel P, Paget-Bailly S, Huguet F, Van Laethem JLuc, Goldstein D, Glimelius B, Artru P, Moore M, Andre T et al..  2014.  Prognosis model for overall survival in locally advanced pancreatic cancer (LAPC): An ancillary study of the LAP 07 trial.. JOURNAL OF CLINICAL ONCOLOGY. 32
Vernerey D, Hammel P, Paget-Bailly S, Huguet F, Van Laethem JLuc, Goldstein D, Glimelius B, Artru P, Moore MJ, Andre T et al..  2015.  Prognosis model for overall survival in locally advanced unresecable pancreatic carcinoma: An ancillary study of the LAP 07 trial. JOURNAL OF CLINICAL ONCOLOGY. 33
Lombardi Y., Boccara F., Baldet K., Lang S., Ederhy S., Nhan P., Riller Q., Chauvet-Droit M., Jean M-L, Adavane-Scheuble S. et al..  2020.  Prognosis of acute kidney injury during acute heart failure: the role of diuretics. EUROPEAN HEART JOURNAL. 41:3319.
Lombardi Y., Boccara F., Baldet K., Lang S., Ederhy S., Nhan P., Riller Q., Chauvet-Droit M., Jean M-L, Adavane-Scheuble S. et al..  2020.  Prognosis of acute kidney injury during acute heart failure: the role of diuretics. EUROPEAN HEART JOURNAL. 41:3319.
Coilly A., Dharancy S., Duvoux C., Martino V.D, Dumortier J, Radenne S., Alric L., Besch C., Francoz C., Perarnaud J. et al..  2018.  Prognosis of ALF of unknown cause: results of the French multicentre prospective HASIPRO study. JOURNAL OF HEPATOLOGY. 68:S68-S69.
Coilly A, Dharancy S, Duvoux C, Cervoni J-P, Dumortier J, Radenne S, Alric L, Besch C, Francoz C, Perarnau JMarc et al..  2018.  Prognosis of Alf of Unknown Cause: Results of the French Multicentre Prospective Hasipro Study. HEPATOLOGY. 68:192A-193A.
Coilly A, Dharancy S, Duvoux C, Cervoni J-P, Dumortier J, Radenne S, Alric L, Besch C, Francoz C, Perarnau JMarc et al..  2018.  Prognosis of Alf of Unknown Cause: Results of the French Multicentre Prospective Hasipro Study. HEPATOLOGY. 68:192A-193A.
Audrey C., Dharancy S., Duvoux C., Di Martino V, Dumortier J., Radenne S., Alric L., Besch C., Francoz C., Perarnaud J. et al..  2018.  Prognosis of ALF of unknown cause: results of the French multicentre prospective HASIPRO study. TRANSPLANTATION. 102:51-52.

Pages